Nadji Hannachi

Dr. Nadji Hannachi

IHU Méditerranée Infection, Marseille, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
Nadji HannachiNadji Hannachi
Nadji Hannachi
GHGilbert Habib
Gilbert Habib
LCLaurence Camoin-Jau
Laurence Camoin-Jau
Infectious endocarditis (IE) is a rare disease associated with high mortality and morbidity rate. The platelet–bacterial interaction presents the cornerstone of the development of endocardial vegetation. The epidemiology of IE has undergone profound changes between the last and the new decade, with Staphylococcus aureus becoming the main incriminated species. Despite improvements in antibiotic and surgical therapies, embolic disorders remain highly associated with IE that can be fatal. Antiplatelet drugs have been widely proposed to overcome embolic events associated with IE. This proposal has been supported by numerous in vitro, experimental, and clinical studies. However, other studies have yielded conflicting results. In this review, we focus on the effect of aspirin on the genesis of S. aureus endocarditic vegetation, as well as on the management of embolic and hemorrhagic events related to it, starting by its influence on the platelet–bacteria interaction.

5 June 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Nadji HannachiNadji Hannachi
Nadji Hannachi
EOEmma Ogé-Ganaye
Emma Ogé-Ganaye
JBJean-Pierre Baudoin
Jean-Pierre Baudoin
AFAnthony Fontanini
Anthony Fontanini
DBDenis Bernot
Denis Bernot
LCLaurence Camoin-Jau
Laurence Camoin-Jau
Platelets are the cornerstone of hemostasis. However, their exaggerated aggregation induces deleterious consequences. In several diseases, such as infectious endocarditis and sepsis, the interaction between platelets and bacteria leads to platelet aggregation. Despite platelet involvement, no antiplatelet therapy is currently recommended in these infectious diseases. We aimed here, to evaluate, in vitro, the effect of antiplatelet drugs on platelet aggregation induced by two of the bacterial pathogens most involved in infectious endocarditis, Staphylococcus aureus and Streptococcus sanguinis. Blood samples were collected from healthy donors (n = 43). Treated platelet rich plasmas were incubated with three bacterial strains of each species tested. Platelet aggregation was evaluated by Light Transmission Aggregometry. CD62P surface exposure was evaluated by flow cytometry. Aggregate organizations were analyzed by scanning electron microscopy. All the strains tested induced a strong platelet aggregation. Antiplatelet drugs showed distinct effects depending on the bacterial species involved with different magnitude between strains of the same species. Ticagrelor exhibited the highest inhibitory effect on platelet activation (p <0.001) and aggregation (p <0.01) induced by S. aureus. In the case of S. sanguinis, platelet activation and aggregation were better inhibited using the combination of both aspirin and ticagrelor (p <0.05 and p <0.001 respectively). Aggregates ultrastructure and effect of antiplatelet drugs observed by scanning electron microscopy depended on the species involved. Our results highlighted that the effect of antiplatelet drugs depended on the bacterial species involved. We might recommend therefore to consider the germ involved before introduction of an optimal antiplatelet therapy.

1 March 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
Nadji HannachiNadji Hannachi
Nadji Hannachi
LGLaettitia Grac
Laettitia Grac
Jean-Pierre BaudoinJean-Pierre Baudoin
Jean-Pierre Baudoin
PFPierre-Edouard Fournier
Pierre-Edouard Fournier
GHGilbert Habib
Gilbert Habib
LCLaurence Camoin-Jau
Laurence Camoin-Jau

4 July 2020 in Platelets
Verified
Journal Article
Closed access
Nadji HannachiNadji Hannachi
Nadji Hannachi
PFPierre-Edouard Fournier
Pierre-Edouard Fournier
HMHélène Martel
Hélène Martel
GHGilbert Habib
Gilbert Habib
LCLaurence Camoin-Jau
Laurence Camoin-Jau
Platelets have largely demonstrated their implication in anti-infectious immunity. This effect is ensured by the secreted molecules stored mostly in platelet alpha granules. Previous studies have reported that Staphylococcus aureus showed sensitivity to this antibacterial effect of platelets. Statins, for their part, have shown a modulating effect on platelet activation. Furthermore, several studies have reported a protective effect of statins in staphylococcal endocarditis. The aim of this study was to investigate the influence of statins on the antibacterial effect of washed platelets. Blood samples were collected from healthy donors (n = 35). PRP was prepared according to the ISTH recommendation. Bacteria were incubated for four hours with untreated-washed platelets, or rather treated by statins and/or GPIIbIIIa antagonists. In order to evaluate the antibacterial effect, the platelet-bacteria mix was spread on the blood agar to count the number of colonies after 18 hours of incubation. Measurement of CD 41 and CD62P expression by flow cytometry was performed to evaluate the effect of statin on bacterial-induced platelet activation. Statins have shown a potentiation of the antibacterial effect of washed platelets (p < .01 for Atorvastatin and Rosuvastatin and p < .001 for Fluvastatin vs untreated washed platelets condition). This effect of statins was dose-dependent and was more significant at 20 μM. The addition of Fluvastatin to platelet-bacterial mix significantly increased the expression of platelet CD41 and CD62P (p < .05 and p < .01 vs resting washed platelets, respectively). Tirofiban, GPIIbIIIa antagonist, reversed the antibacterial effect of washed platelets and suppressed the potentiating effect of statins. Our study demonstrated that statins potentiate the anti-staphylococcal effect of washed platelets. This result may explain the beneficial effect of statins on Staphylococcus aureus infective endocarditis. Further studies are therefore required to explain this effect at the molecular level and to assess its impact in vivo.

19 December 2019 in Platelets
Verified
Journal Article
Closed access
Nadji HannachiNadji Hannachi
Nadji Hannachi
Jean-Pierre BaudoinJean-Pierre Baudoin
Jean-Pierre Baudoin
APArsha Prasanth
Arsha Prasanth
GHGilbert Habib
Gilbert Habib
LCLaurence Camoin-Jau
Laurence Camoin-Jau
Bacteria induce platelet aggregation triggered by several mechanisms. The goal of this work was to characterize platelet aggregates induced by different bacterial strains and to quantify the effect of aspirin treatment using aggregation tests, as well as a novel approach based on confocal analysis. Blood samples were obtained from either healthy donors (n = 27) or patients treated with long-term aspirin (n = 15). The bacterial species included were Staphylococcus aureus, Enterococcus faecalis, and Streptococcus sanguinis. The different aggregate’s ultrastructures depending on the bacterial strain were analyzed using Scanning electron microscopy. Quantification of the size of the platelet aggregates, their mean number as well as the bacterial impregnation within the aggregates was performed using confocal laser scanning light microscopy. Light Transmission Aggregometry was also performed. Our results reported distinct characteristics of platelet aggregates depending on the bacterial strain. Using confocal analysis, we have shown that aspirin significantly reduced platelet aggregation induced by S. aureus (p = .003) and E. faecalis (p = .006) with no effect in the case of S. sanguinis (p = .529). The results of the aggregometry were concordant with those of the confocal technique in the case of S. aureus and S. sanguinis. Interestingly, aggregation induced by E. faecalis was detected only with confocal analysis. In conclusion, our confocal scanning microscopy allowed a detailed study of the platelet aggregation induced by bacteria. We showed that aspirin acts on bacterial-induced platelet aggregation depending on the species. These results are in favor of the use of aspirin considering the species and the bacterial strain involved.

4 August 2020 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
Jean-Pierre BaudoinJean-Pierre Baudoin
Jean-Pierre Baudoin
LCLaurence Camoin-Jau
Laurence Camoin-Jau
APArsha Prasanth
Arsha Prasanth
GHGilbert Habib
Gilbert Habib
HLHubert Lepidi
Hubert Lepidi
Nadji HannachiNadji Hannachi
Nadji Hannachi